Ovid Therapeutics Inc
NASDAQ:OVID

Watchlist Manager
Ovid Therapeutics Inc Logo
Ovid Therapeutics Inc
NASDAQ:OVID
Watchlist
Price: 1.67 USD -3.47% Market Closed
Market Cap: 118.9m USD

Wall Street
Price Targets

OVID Price Targets Summary
Ovid Therapeutics Inc

Wall Street analysts forecast OVID stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for OVID is 4.26 USD with a low forecast of 2.02 USD and a high forecast of 7.35 USD.

Lowest
Price Target
2.02 USD
21% Upside
Average
Price Target
4.26 USD
155% Upside
Highest
Price Target
7.35 USD
340% Upside
Ovid Therapeutics Inc Competitors:
Price Targets
FOLD
Amicus Therapeutics Inc
14% Upside
688266
Suzhou Zelgen Biopharmaceuticals Co Ltd
50% Upside
KURA
Kura Oncology Inc
258% Upside
IPH
Innate Pharma SA
228% Upside
VLA
Valneva SE
58% Upside
CRVO
Diffusion Pharmaceuticals Inc
196% Upside
PHM
Pharma Mar SA
26% Upside
FYB
Formycon AG
94% Upside

Revenue
Forecast

Revenue Estimate
Ovid Therapeutics Inc

The compound annual growth rate of Ovid Therapeutics Inc's revenue for the next 4 years is -31%.

N/A
Past Growth
-31%
Estimated Growth
Estimates Accuracy
0%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Ovid Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Net Income
Forecast

Net Income Estimate
Ovid Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-16%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is OVID's stock price target?
Price Target
4.26 USD

According to Wall Street analysts, the average 1-year price target for OVID is 4.26 USD with a low forecast of 2.02 USD and a high forecast of 7.35 USD.

What is Ovid Therapeutics Inc's Revenue forecast?
Projected CAGR
-31%

The compound annual growth rate of Ovid Therapeutics Inc's revenue for the next 4 years is -31%.

Back to Top